Abeona Therapeutics Inc
Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $55.31 million
- Book Value:
- Revenue TTM:
- $4.35 million
- Operating Margin TTM:
- Gross Profit TTM:
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Abeona Therapeutics Inc had its IPO on 1980-09-19 under the ticker symbol ABEO.
The company operates in the Healthcare sector and Biotechnology industry. Abeona Therapeutics Inc has a staff strength of 90 employees.
Shares of Abeona Therapeutics Inc opened at $2.74 at the start of the last trading session i.e. 2023-03-30.
The stocks traded within a range of $2.72 - $2.9, and closed at $2.83.
This is a +0.71% increase from the previous day's closing price.
A total volume of 135,450 shares were traded at the close of the day’s session.
In the last one week, shares of Abeona Therapeutics Inc have increased by +17.92%.
Abeona Therapeutics Inc's Key Ratios
Abeona Therapeutics Inc has a market cap of $55.31 million, indicating a price to book ratio of 3.3097 and a price to sales ratio of 10.7102.
In the last 12-months Abeona Therapeutics Inc’s revenue was $4.35 million with a gross profit of $-31325000 and an EBITDA of $-44286000. The EBITDA ratio measures Abeona Therapeutics Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Abeona Therapeutics Inc’s operating margin was -1091.97% while its return on assets stood at -37.6% with a return of equity of -179.18%.
In Q3, Abeona Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Abeona Therapeutics Inc’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $-19.38 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Abeona Therapeutics Inc’s profitability.
Abeona Therapeutics Inc stock is trading at a EV to sales ratio of 9.466 and a EV to EBITDA ratio of -0.5151. Its price to sales ratio in the trailing 12-months stood at 10.7102.
Abeona Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $38.76 million
- Total Liabilities
- $12.60 million
- Operating Cash Flow
- $1.65 million
- Capital Expenditure
- Dividend Payout Ratio
Abeona Therapeutics Inc ended 2023 with $38.76 million in total assets and $0 in total liabilities. Its intangible assets were valued at $38.76 million while shareholder equity stood at $15.41 million.
Abeona Therapeutics Inc ended 2023 with $0 in deferred long-term liabilities, $12.60 million in other current liabilities, 77000.00 in common stock, $-694210000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $5.73 million and cash and short-term investments were $18.17 million. The company’s total short-term debt was $1,810,000 while long-term debt stood at $0.
Abeona Therapeutics Inc’s total current assets stands at $25.50 million while long-term investments were $0 and short-term investments were $12.43 million. Its net receivables were $1.05 million compared to accounts payable of $1.75 million and inventory worth $0.
In 2023, Abeona Therapeutics Inc's operating cash flow was $1.65 million while its capital expenditure stood at $2000.
Comparatively, Abeona Therapeutics Inc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Abeona Therapeutics Inc stock is currently trading at $2.83 per share. It touched a 52-week high of $9.355 and a 52-week low of $9.355. Analysts tracking the stock have a 12-month average target price of $29.
Its 50-day moving average was $2.55 and 200-day moving average was $3.56 The short ratio stood at 2.69 indicating a short percent outstanding of 0%.
Around 549.4% of the company’s stock are held by insiders while 4683.6% are held by institutions.
Frequently Asked Questions About Abeona Therapeutics Inc
Similar Industry Stocks (Biotechnology)
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A; ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-50X for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1974 and is headquartered in New York, New York.